Abstract
Cardiometabolic diseases impose substantial healthcare costs; therefore, the need for investigations into the underlying hormonal and molecular mechanisms is unequivocal and should be guided by the identification of innovative molecules acting through pathways not yet targeted by currently available pharmacotherapies, given the high morbidity and mortality rates. Recent evidence indicates…